On November 13, IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct the Phase II clinical study of the medicinal product AB5080. Protocol FLU-AV5080-02 “Multicenter, randomized, double-blind, placebo-controlled study to assess efficacy, safety and optimal dose of the drug AB5080 in patients with influenza”. The study objective is to evaluate the efficacy, safety and optimal dose of the drug AB5080 in patients with influenza. Therapeutic a

On June 2, ASCO Annual Meeting 2017, the main event of the year for specialists in the field of oncology, had started. Annually in Chicago, USA, more than 30,000 medical and pharmaceutical workers gather to discuss modern methods of treatment and innovative drugs. This year, the congress will present the results of a multicenter, open-label Phase II safety and efficacy study of Quizinostat in combination with Paclitaxel + Carboplatin chemotherapy in patients with metastati

On September 12, 2016, IPHARMA was authorized by the Ministry of Health of the Russian Federation to conduct the Phase IIa clinical trial of the medicinal product VM-1011. Protocol № HBV-VM1011-02 "A partially-blind randomized comparative pilot clinical trial of antiviral activity, safety and dosing of VM-1011 compared to tenofovir in treatment-naive patients with chronic viral hepatitis B". The aim of the clinical trial is to studythe antiviral activity, safety and dosing of

On May 5th, 2016, IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct the Phase II clinical study of the medicinal product Quisinostat. Protocol № ONC-14-NSCLCII-1-1QUI-3 "Multicenter double-blind randomized placebo-controlled Phase II clinical study with the combination of Gemcitabine, Cisplatin and Quisinostat versus Gemcitabine, Cisplatin and placebo in 1st line treatment of patients with advanced Stage IIIb-IV squamous NSCLC". The stu